KIT and melanoma: Moreover, based on our data, we speculate that quizartinib may be a promising agent in solid tumors associated with KIT mutations, such as GIST or melanoma: In addition to a favorable activity against KIT mutant kinases expressed in GIST (and other mutant-KIT neoplasms), the excellent pharmacokinetics with unprecedented achievable plasma concentrations may be advantageous to target bulky solid tumor lesions that have impaired drug uptake.